SCHEMBL2364522

SCHEMBL2364522

COc1ccc(OS(=O)(=O)C(F)(F)F)c([N+](=O)[O-])c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.49
ALDH1A1 P00352 3/20 0.48
MAPK1 P28482 2/20 0.48
AKR1C3 P42330 3/20 0.46
AKR1C2 P52895 3/20 0.46
MAPT P10636 3/20 0.45
RAB9A P51151 3/20 0.45
NPC1 O15118 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
THRB P10828 1/20 0.44
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.44
MCOLN3 Q8TDD5 1/20 0.44
ALDH3A1 P30838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31090817 1.00 PTPN1 (0.49) PTPN1ALDH1A1MAPK1AKR1C3AKR1C2
SCHEMBL3434984 0.92 PTPN1 (0.46) PTPN1ALDH1A1MAPK1AKR1C3AKR1C2
SCHEMBL3434990 0.86 PTPN1 (0.49) PTPN1ALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL12777011 0.84 ALDH1A1 (0.46) PTPN1ALDH1A1MAPK1MAPTMEN1
SCHEMBL31090816 0.83 TSHR (0.49) PTPN1ALDH1A1MAPK1MAPTRAB9A
SCHEMBL810810 0.83 TSHR (0.49) PTPN1ALDH1A1MAPK1MAPTRAB9A
SCHEMBL28090116 0.82 ALDH1A1 (0.52) ALDH1A1MAPK1AKR1C3AKR1C2MAPT
SCHEMBL229088 0.81 HSPB1 (0.47) PTPN1ALDH1A1MEN1KMT2AALDH3A1
SCHEMBL31090808 0.81 HSPB1 (0.47) PTPN1ALDH1A1MEN1KMT2AALDH3A1
SCHEMBL8616810 0.81 HSPB1 (0.51) PTPN1ALDH1A1MAPK1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190082845-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON INC (US) 2019-03-21 US disclosed
US-10137109-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, INC. (US) 2018-11-27 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
EP-2356093-B1 Carbazole compounds and therapeutic uses of the compounds INCURON LLC (RU) 2013-01-09 EP disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
EP-2356093-A1 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (RU) 2011-08-17 EP disclosed
WO-2010042445-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS CLEVELAND BIOLABS, INC. (US) 2010-04-15 WO disclosed
EP-1178989-A1 PROCESS FOR MAKING FUSED-RING IMIDAZO-CONTAINING COMPOUNDS The Procter & Gamble Company (US) 2002-02-13 EP disclosed
WO-2000069857-A1 PROCESS FOR MAKING FUSED-RING IMIDAZO-CONTAINING COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 PTPN1 4236/4885ALDH1A1 633/4885MAPK1 2936/4885
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 PTPN1 4236/4885ALDH1A1 633/4885MAPK1 2936/4885
US-10137109-B2 Carbazole compounds and therapeutic uses of the compounds MALT1, PAICS, BCL9 PTPN1 4236/4885ALDH1A1 633/4885MAPK1 2936/4885
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds MALT1, PAICS, TPMT PTPN1 4197/4885ALDH1A1 589/4885MAPK1 3016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.